Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
22 Noviembre 2022 - 7:35AM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the
“Company”), a clinical-stage biotechnology company developing
eganelisib, a first-in-class, oral, immuno-oncology macrophage
reprogramming therapeutic, today announced that the Company will
present and conduct 1-on-1 meetings with investors at the Piper
Sandler 34th Annual Healthcare Conference taking place November 29
– December 1, 2022 in New York.
Piper Sandler 34th Annual Healthcare Conference Date:
Tuesday, November 29, 2022 Time: 4:00 p.m. ET Speaker: Adelene
Perkins, Chief Executive Officer Format: In-person fireside chat
and 1-on-1 meetings
https://event.webcasts.com/starthere.jsp?ei=1584856&tp_key=e9a7246381
A replay of the presentation will be available in the
Investors/Media section of Infinity's website at www.infi.com for
90 days following the event.
About Infinity and Eganelisib Infinity Pharmaceuticals,
Inc. (“Infinity” or the “Company”), is a clinical-stage
biotechnology company developing eganelisib (IPI-549), a
first-in-class, oral, immuno-oncology macrophage reprogramming
therapeutic which is designed to address a fundamental biologic
mechanism of immune suppression in cancer in multiple clinical
studies. MARIO-3 is the first eganelisib combination study in
front-line advanced cancer patients and is evaluating eganelisib in
combination with Tecentriq® and Abraxane® in front-line TNBC and in
combination with Tecentriq and Avastin® in front-line RCC.
MARIO-275 is a randomized, controlled combination study of
eganelisib combined with Opdivo® in I/O naïve urothelial cancer.
For more information on Infinity, please refer to Infinity's
website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane®
is a registered trademark of Abraxis BioScience, LLC., a wholly
owned subsidiary of Bristol Myers Squibb Company. Avastin® is a
registered trademark of Genentech, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221122005211/en/
Investor Relations: Luke Heagle Real Chemistry
lheagle@realchemistry.com
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024